Comparative Effectiveness between Dipeptidylpeptidase-4 Inhibitors and Sulfonylureas in Combination with Metformin in Type 2 Diabetes Mellitus Patients
![]() |
Park, Ji Hye
(Division of Pharmaceutical Services, Asan Medical Center)
Park, Sunny (College of Pharmacy & Division of Life and Pharmaceutical Sciences, Ewha Womans University) Kim, Jae Youn (Division of Pharmaceutical Services, Asan Medical Center) Kim, Joo Hee (College of Pharmacy & Division of Life and Pharmaceutical Sciences, Ewha Womans University) Gwak, Hye Sun (Graduate School of Clinical Health Sciences, Ewha Womans University) |
1 | Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375(9733): 2215-22. DOI |
2 | Morrish, NJ, Wang, SL, Stevens, LK, et al. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 2001;44(Suppl. 2):S14-S21. DOI |
3 | Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;32(7258):405-12. |
4 | Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med 2010;27(3):318-26. DOI |
5 | Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010; 64(5):562-76. DOI |
6 | Gallwitz B, Rosenstock J, Emser A, et al. Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA1c < 7% with no hypoglycaemia and no weight gain over 2 years. Int J Clin Pract 2013;67(4):317-21. DOI |
7 | Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012;344:e1369-83. DOI |
8 | Zhang Y, Hong J, Chi J, et al. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials. Diabetes Metab Res Rev 2014;30(3):241-56. DOI |
9 | Rathmann W, Kostev K, Gruenberger JB, et al. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. Diabetes Obes Metab 2013;15(1):55-61. DOI |
10 | Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol 2012;110(6):826-33. DOI |
11 | Green JB, Bethel MA, Paul SK, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TESCO) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J 2013;166(6):983-9. DOI |
12 | Hirst JA, Farmer AJ, Dyar A, et al. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia 2013;56(5):973-84. DOI |
13 | Sherifali D, Nerenberg K, Pullenayegum E, et al. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care 2010;33(8):1859-64. DOI |
14 | Park H, Park C, Kim Y, et al. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother 2012;46(11):1453-69. DOI |
15 | DeFronzo RA, Stonehouse AH, Han J, et al. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med 2010;27(3):309-317. DOI |
16 | Morgan CL, Mukherjee J, Jenkins-Jones S, et al. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. Diabetes Obes Metab 2014;16(10):977-83. DOI |
17 | Bloomgarden ZT, Dodis R, Viscoli CM, et al. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy. Diabetes Care 2006;29(9):2137-9. DOI |
18 | Esposito K, Cozzolino D, Bellastella G, et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of < 7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab 2011;13(7):594-603. DOI |
19 | Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15(10):938-53. DOI |
20 | Yu OH, Yin H, Azoulay L. The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death. Can J Diabetes 2015, Epub ahead of print. |
![]() |